We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Imbrium Therapeutics

News List

Eisai and ImFDA Filing Acceptance of New Drug Application for Lemborexant for the Treatment of Insomnia pharmafocusasia
March 12, 2019
Eisai Co., Ltd. and Imbrium Therapeutics L.P., a clinical-stage biopharmaceutical company and operating subsidiary of Purdue Pharma L.P.
Imbrium Therapeutics and TetraGenetics Announce Strategic Research Collaboration and License Option to Develop Novel Biologic Therapeutics pharmafocusasia
February 28, 2019
Imbrium Therapeutics L.P., a clinical-stage biopharmaceutical company and operating subsidiary of Purdue Pharma L.P., and TetraGenetics, Inc....
Purdue Pharma taps TetraGenetics for ion channel-focused pain treatments in $273M discovery pact fiercebiotech
February 27, 2019
Purdue Pharma’s newly formed clinical research subsidiary, Imbrium Therapeutics, has tapped TetraGenetics and its antibody discovery platform to help it develop new, non-opioid-based biologics for treating chronic pain....